Titanovo Logo
Back to Cell Types

NCI-H2009Homo sapiens (Human)Cancer cell line

Also known as: NCIH2009, H-2009, H2009

🤖 AI SummaryBased on 12 publications

Quick Overview

Human lung cancer cell line with known mutations and drug sensitivity profiles.

Detailed Summary

The NCI-H2009 cell line is a human lung cancer cell line derived from a small cell lung cancer (SCLC) tumor. It is widely used in cancer research for studying the molecular mechanisms of SCLC and for testing the efficacy of targeted therapies. This cell line has been characterized in multiple studies, including those focusing on proteomic profiling, gene expression, and drug response. Research has identified specific mutations and pathways associated with this cell line, making it a valuable model for understanding SCLC biology and developing new therapeutic strategies. The cell line is also part of large-scale cancer cell line databases, such as the Cancer Cell Line Encyclopedia (CCLE), which provides comprehensive genomic and pharmacological data for research purposes.

Research Applications

Proteomic profilingGene expression analysisDrug sensitivity testingMolecular mechanism studies

Key Characteristics

Small cell lung cancer (SCLC) modelKnown mutations in key oncogenesPart of large cancer cell line databases
Generated on 6/17/2025

Basic Information

Database IDCVCL_1514
SpeciesHomo sapiens (Human)
Tissue SourceLymph node[UBERON:UBERON_0000029]

Donor Information

Age68
Age CategoryAdult
SexFemale
Racecaucasian

Disease Information

DiseaseLung adenocarcinoma
LineageLung
SubtypeLung Adenocarcinoma
OncoTree CodeLUAD

DepMap Information

Source TypeATCC
Source IDACH-000886_source

Known Sequence Variations

TypeGene/ProteinDescriptionZygosityNoteSource
MutationSimpleTP53p.Arg273Leu (c.818G>T)HomozygousSomatic mutation acquired during proliferationPubMed=31541927, PubMed=23613873, PubMed=15735012
MutationSimpleTERTc.1-124C>T (c.228C>T) (C228T)UnspecifiedIn promoterfrom parent cell line Hep-G2
MutationSimpleKRASp.Gly12Ala (c.35G>C)Unspecified-PubMed=21173094
MutationSimpleB2Mp.Gln28Ter (c.82C>T)Homozygous-Unknown, Unknown
MutationSimpleB2Mp.Met1Val (c.1A>G)Heterozygous-from parent cell line NCI-H2009

Haplotype Information (STR Profile)

Short Tandem Repeat (STR) profile for cell line authentication.

Amelogenin
X
CSF1PO
10,12
D13S317
12
D16S539
12
D18S51
14
D19S433
14,16,17
D21S11
29
D2S1338
16,19
D3S1358
16
D5S818
13
D7S820
9,11
D8S1179
10,15
FGA
22
Penta D
12
Penta E
11
TH01
9.3
TPOX
8
vWA
14
Gene Expression Profile
Gene expression levels and statistical distribution
Loading cohorts...
Full DepMap dataset with combined data across cell lines

Loading gene expression data...

Publications

Pan-cancer proteomic map of 949 human cell lines.";

Robinson P.J., Zhong Q., Garnett M.J., Reddel R.R.

Cancer Cell 40:835-849.e8(2022).

DOIPubMedPMC

Quantitative proteomics of the Cancer Cell Line Encyclopedia.";

Sellers W.R., Gygi S.P.

Cell 180:387-402.e16(2020).

DOIPubMedPMC

From clinical specimens to human cancer preclinical models -- a journey the NCI-cell line database-25 years later.

Aldige C.R., Wistuba I.I., Minna J.D.

J. Cell. Biochem. 121:3986-3999(2020).

DOIPubMedPMC

Next-generation characterization of the Cancer Cell Line Encyclopedia.

Sellers W.R.

Nature 569:503-508(2019).

DOIPubMedPMC

An interactive resource to probe genetic diversity and estimated ancestry in cancer cell lines.

Dutil J., Chen Z.-H., Monteiro A.N.A., Teer J.K., Eschrich S.A.

Cancer Res. 79:1263-1273(2019).

DOIPubMedPMC

LMO1 functions as an oncogene by regulating TTK expression and correlates with neuroendocrine differentiation of lung cancer.

Minna J.D., Wistuba I.I., Pertsemlidis A.

Oncotarget 9:29601-29618(2018).

DOIPubMedPMC

Chemistry-first approach for nomination of personalized treatment in lung cancer.

Posner B.A., Minna J.D., Kim H.S., White M.A.

Cell 173:864-878.e29(2018).

DOIPubMedPMC

Differential effector engagement by oncogenic KRAS.";

McCormick F.

Cell Rep. 22:1889-1902(2018).

DOIPubMedPMC

A landscape of pharmacogenomic interactions in cancer.";

Wessels L.F.A., Saez-Rodriguez J., McDermott U., Garnett M.J.

Cell 166:740-754(2016).

DOIPubMedPMC

TCLP: an online cancer cell line catalogue integrating HLA type, predicted neo-epitopes, virus and gene expression.

Loewer M., Sahin U., Castle J.C.

Genome Med. 7:118.1-118.7(2015).

DOIPubMedPMC

A resource for cell line authentication, annotation and quality control.

Neve R.M.

Nature 520:307-311(2015).

DOIPubMed

A comprehensive transcriptional portrait of human cancer cell lines.

Settleman J., Seshagiri S., Zhang Z.-M.

Nat. Biotechnol. 33:306-312(2015).

DOIPubMed

Reconstructing targetable pathways in lung cancer by integrating diverse omics data.

Cao X.-H., Nesvizhskii A.I., Chinnaiyan A.M.

Nat. Commun. 4:2617.1-2617.13(2013).

DOIPubMedPMC

Proteomic profiling identifies dysregulated pathways in small cell lung cancer and novel therapeutic targets including PARP1.

Heymach J.V.

Cancer Discov. 2:798-811(2012).

DOIPubMedPMC

The Cancer Cell Line Encyclopedia enables predictive modelling of anticancer drug sensitivity.

Morrissey M.P., Sellers W.R., Schlegel R., Garraway L.A.

Nature 483:603-607(2012).

DOIPubMedPMC

Prevalence of human papillomavirus 16/18/33 infection and p53 mutation in lung adenocarcinoma.

Iwakawa R., Kohno T., Enari M., Kiyono T., Yokota J.

Cancer Sci. 101:1891-1896(2010).

DOIPubMedPMC

A genome-wide screen for microdeletions reveals disruption of polarity complex genes in diverse human cancers.

Haber D.A.

Cancer Res. 70:2158-2164(2010).

DOIPubMedPMC

Signatures of mutation and selection in the cancer genome.";

Deloukas P., Yang F.-T., Campbell P.J., Futreal P.A., Stratton M.R.

Nature 463:893-898(2010).

DOIPubMedPMC

A gene-alteration profile of human lung cancer cell lines.";

Montuenga L.M., Minna J.D., Yokota J., Sanchez-Cespedes M.

Hum. Mutat. 30:1199-1206(2009).

DOIPubMedPMC

High resolution analysis of non-small cell lung cancer cell lines by whole genome tiling path array CGH.

Gazdar A.F., Lam S., MacAulay C., Lam W.L.

Int. J. Cancer 118:1556-1564(2006).

DOIPubMed

Chromosome abnormalities in 10 lung cancer cell lines of the NCI-H series analyzed with spectral karyotyping.

Grigorova M., Lyman R.C., Caldas C., Edwards P.A.W.

Cancer Genet. Cytogenet. 162:1-9(2005).

DOIPubMed

Mutations of the BRAF gene in human cancer.";

Marshall C.J., Wooster R., Stratton M.R., Futreal P.A.

Nature 417:949-954(2002).

DOIPubMed

Short tandem repeat profiling provides an international reference standard for human cell lines.

Harrison M., Virmani A.K., Ward T.H., Ayres K.L., Debenham P.G.

Proc. Natl. Acad. Sci. U.S.A. 98:8012-8017(2001).

DOIPubMedPMC

Searching for microsatellite mutations in coding regions in lung, breast, ovarian and colorectal cancers.

Minna J.D.

Oncogene 20:1005-1009(2001).

DOIPubMed

Protein expression of the RB-related gene family and SV40 large T antigen in mesothelioma and lung cancer.

Modi S., Kubo A., Oie H.K., Coxon A.B., Rehmatulla A., Kaye F.J.

Oncogene 19:4632-4639(2000).

DOIPubMed

Genome-wide allelotyping of lung cancer identifies new regions of allelic loss, differences between small cell lung cancer and non-small cell lung cancer, and loci clustering.

Girard L., Zochbauer-Muller S., Virmani A.K., Gazdar A.F., Minna J.D.

Cancer Res. 60:4894-4906(2000).

PubMed

Allelotyping demonstrates common and distinct patterns of chromosomal loss in human lung cancer types.

Minna J.D., Gazdar A.F.

Genes Chromosomes Cancer 21:308-319(1998).

DOIPubMed

NCI-Navy Medical Oncology Branch cell line data base.";

Carney D.N., Minna J.D., Mulshine J.L.

J. Cell. Biochem. Suppl. 24:32-91(1996).

DOIPubMed

p53 gene mutations in non-small-cell lung cancer cell lines and their correlation with the presence of ras mutations and clinical features.

Gazdar A.F.

Oncogene 7:171-180(1992).

PubMed

Web Resources

cellosaurus.org